Do bisphosphonates and statins have a role in spondyloarthritis management?
Bisphosphonates and statins target the mevalonate pathway of biosynthesis of prenyl groups, which are necessary for the lipid modification of small GTP-binding proteins (eg, Ras, Rac, Rho) that transduce a wide array of extracellular growth and differentiation signals from cell surface receptors to the nucleus. Interference with this pathway has been shown to confer beneficial anti-inflammatory properties in vitro and in animal models of inflammation. Primarily open-label data in spondylo-arthritis suggests mild to moderate efficacy on symptoms and function but their primary clinical role may be as adjunctive therapy to manage systemic osteoporosis and risk for cardiovascular events.
Maksymowych
Walter P
WP
University of Alberta, Edmonton, Alberta T6G 2S2, Canada. walter.maksymowych@ualberta.ca
D000818:Animals; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D004164:Diphosphonates / Q000627:therapeutic use*; D004195:Disease Models, Animal; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D025242:Spondylarthropathies / Q000188:drug therapy*
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors